Laboratory Tests for Cervical Cytology with HPV Co-Testing
For cervical cancer screening with high-risk HPV DNA co-testing, order: (1) Cervical cytology (Pap test) and (2) High-risk HPV DNA testing for 13-14 oncogenic HPV types on the laboratory requisition form.
Specific Tests to Order
Primary Tests Required
Both tests should be ordered together for women aged ≥30 years 1, 2:
- Cervical cytology (Pap test) - using either liquid-based or conventional cytology methods
- High-risk HPV DNA test - detecting 13-14 high-risk HPV types (16,18,31,33,35,39,45,51,52,56,58,59,66,68)
FDA-Approved HPV Tests
The laboratory requisition should specify one of these validated high-risk HPV DNA tests 1:
- Hybrid Capture 2 High-Risk HPV DNA test (Qiagen) - detects 13 high-risk types
- Cervista HPV High-Risk test (Hologics) - detects 13-14 high-risk types
- BD Onclarity HPV Assay 3
- Cobas 4800 HPV Test 3
- Abbott RealTime High Risk HPV 3
- Xpert HPV 3
Age-Specific Ordering Guidelines
Women Aged 30-65 Years
Co-testing (cytology + HPV) every 5 years is the preferred approach 2. The requisition should include:
- Cervical cytology
- High-risk HPV DNA testing
This combination allows for 5-year screening intervals when both tests are negative 1.
Women Aged 21-29 Years
Order cytology alone every 2 years 2. HPV testing should NOT be ordered for routine screening in this age group 1. The only exception is using HPV testing for triage of ASC-US cytology results in women ≥21 years 1.
Critical Specifications for the Lab Requisition
What NOT to Order
Do not order low-risk HPV testing - only high-risk types are clinically useful for screening 1, 4. Testing for low-risk HPV types (6,11) has no role in cancer screening and may cause unnecessary patient anxiety 4.
Optional Add-On Testing
HPV 16/18 genotyping can be added as reflex testing for specific triage situations 2:
- When cytology is negative but high-risk HPV is positive in women ≥30 years
- This helps determine whether immediate colposcopy is needed (HPV 16/18 positive) or 12-month follow-up is appropriate (other high-risk types)
However, HPV 16/18 genotyping should NOT be used to triage women with ASC-US who are already high-risk HPV positive - these women should proceed directly to colposcopy 2.
Common Pitfalls to Avoid
Don't order HPV testing alone without cytology for primary screening - this is not recommended 1. Co-testing provides optimal sensitivity and specificity.
Don't order HPV testing in women <21 years - even if sexually active, this leads to overdetection of transient infections and unnecessary interventions 1, 2, 1.
Ensure the lab uses validated assays - only FDA-approved tests meeting international validation criteria should be used 3, 5. The test must detect at least 13-14 high-risk HPV types with clinical sensitivity for CIN2+ ≥90% 6.
Specify collection method - clinician-collected cervical specimens are preferred over self-collected vaginal specimens for co-testing, as self-collected samples require different follow-up intervals 7.
Test Performance Characteristics
High-risk HPV testing has approximately 25% higher sensitivity but 10% lower specificity compared to cytology alone for detecting high-grade lesions 4. The combination of both tests (co-testing) provides:
- 98.1% sensitivity for CIN3+ with HPV testing 8
- 96.5% specificity with cytology 8
- Very high negative predictive value when both are negative, justifying extended 5-year screening intervals 4
The requisition form should clearly indicate both tests are needed to achieve this optimal balance of sensitivity and specificity for detecting cervical precancer.